Extended indication Osimertinib with platinum plus pemetrexed chemotherapy as first-line treatment for adult patients wi
Therapeutic value No estimate possible yet
Total cost 37,963,682.26
Registration phase Clinical trials

Product

Active substance Osimertinib
Domain Oncology
Reason of inclusion Indication extension
Main indication Lung cancer
Extended indication Osimertinib with platinum plus pemetrexed chemotherapy as first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.
Proprietary name Tagrisso
Manufacturer AstraZeneca
Portfolio holder AstraZeneca
Mechanism of action Tyrosine kinase inhibitor
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
ATMP No
Submission date 2023
Expected Registration 2024
Orphan drug No
Registration phase Clinical trials
Additional remarks Fabrikant verwacht indiening in de 2023 en registratie in 2024.

Therapeutic value

Current treatment options Osimertinib
Therapeutic value No estimate possible yet
Substantiation De FLAURA2 studie loopt op dit moment nog.
Frequency of administration 1 times a day
Dosage per administration Osimertinib 80 mg in combination with pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
References FLAURA2 (NCT04035486).

Expected patient volume per year

Patient volume

369 - 737

Market share is generally not included unless otherwise stated.

References NKR2018 (1); Pakketadvies sluisgeneesmiddel atezolizumab (Tecentriq®) bij gemetastaseerde niet-kleincellige longkanker. ZIN. 2018 (2); Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer (3);
Additional remarks In 2018 waren er 10.190 diagnoses NSCLC in Nederland. Dit betrof 1.724 stadium I, 921 stadium II, 2.452 stadium III (waarvan zo'n 55% stadium IIIa en zo'n 45% stadium IIIb), 5.062 stadium IV en 31 onbekend. Uitgaande van stadium IIIb / IV komt dat neer op zo'n 6.165 patiënten (1). Hier komen nog patiënten bij uit eerdere stadia die verslechteren naar stadium IIIb/IV. Binnen een jaar is de inschatting dat dit 20% van stadium I/II bedraagt (529 patiënten) en 50% van stadium IIIa (674 patiënten). In totaal bedraagt deze groep dus zo'n 7.369 patiënten (2). Het aantal NSCLC patiënten met EGFR betreft zo'n 5 tot 10% van deze patiënten (3)

Expected cost per patient per year

Cost 68,650.42
References Prijs per 1 januari 2021 (Z-Index/G-standaard februari 2021)
Additional remarks Berekening: €5.642,50 per 30 tabletten. Komt neer op €5.642,50*(365/30)=€ 68.650,42 per patiënt per jaar. Voor osimertinib is een financieel arrangement afgesloten bij de indicaties "Niet eerder behandelde uitgezaaide EGFR-positieve longkanker (NSCLC)" en "Adjuvante behandeling bij EGFR-positieve longkanker (NSCLC)" die afloopt op 31 december 2025 (Staatscourant 2022, 5825).

Potential total cost per year

Total cost

37,963,682.26

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.